Sign in to view content

PER-001, a Long-acting Endothelin Antagonist Intravitreal Implant, Improved Structure and Visual Function in Patients With Diabetic Retinopathy

Justis P. Ehlers, MD, FASRS

Video
Published 2025

Related

1-Year Results of a Phase 2 Pharmacodynamic Study: Subretinal Delivery of Investigational Gene Therapy ABBV-RGX-314 for Neovascular AMD
Robert L. Avery, MD
Updates from the Field
2025
Impact of PRAME Status on Gene Expression Profile to Predict Metastasis in Uveal Melanoma: Interim Analysis of the Collaborative Ocular Oncology Group Study Number 2 (COOG2)
Prithvi Mruthyunjaya, MD, MHS
Updates from the Field
2022
Risk of Diabetic Retinopathy Progression in Patients During 1 year of Semaglutide Use
Blake A. Cooper, MD MPH
Updates from the Field
2022

Category: Diabetic Retinopathy

See more